Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC
UNC Lineberger Comprehensive Cancer Center
University of Maryland, Baltimore
NRG Oncology
Royal Marsden NHS Foundation Trust
H. Lee Moffitt Cancer Center and Research Institute
University of Kentucky
University of Arkansas
Sanford Health
Dana-Farber Cancer Institute
University of Pittsburgh
Numab Therapeutics AG
Memorial Sloan Kettering Cancer Center
University of Chicago
M.D. Anderson Cancer Center
Galderma R&D
Regeneron Pharmaceuticals
LEO Pharma
University of Pittsburgh
Intensity Therapeutics, Inc.
University of Pittsburgh
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
University of Arizona
Washington University School of Medicine
University of Arizona
Icahn School of Medicine at Mount Sinai
Merck Sharp & Dohme LLC
University of Pittsburgh
University of Oxford
Federation Francophone de Cancerologie Digestive
Advaxis, Inc.
Advaxis, Inc.
UNC Lineberger Comprehensive Cancer Center
Pfizer
Memorial Sloan Kettering Cancer Center
Pfizer
Genmab
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
University of Wisconsin, Madison
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Vidac Pharma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Soligenix
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute